Sacituzumab Earns Regular FDA Approval for TNBC - NCI
![](https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_enlarged/public/cgov_image/media_image/2021-05/Trodelvy-Mechanism.png?h=fda58130&itok=XWfSUV0t)
Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
![](https://www.empr.com/wp-content/uploads/sites/7/2020/05/Trodelvy-featured-image.png)
FDA Grants Full Approval to Trodelvy for Triple-Negative Breast Cancer
Clinical Review - Sacituzumab Govitecan (Trodelvy) - NCBI Bookshelf
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-23793-7/MediaObjects/41467_2021_23793_Fig6_HTML.png)
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
![](https://i1.rgstatic.net/publication/360535854_Analysis_of_patients_without_and_with_an_initial_triple-negative_breast_cancer_diagnosis_in_the_phase_3_randomized_ASCENT_study_of_sacituzumab_govitecan_in_metastatic_triple-negative_breast_cancer/links/627c6543107cae29199e4014/largepreview.png)
PDF) Analysis of patients without and with an initial triple
![](https://1.bp.blogspot.com/-WNMK84zoKXw/XWL5UYPVBoI/AAAAAAAAUUY/MY-SIVB5A2EPbO8kyEoa4DOuVb3AbIdtACLcBGAs/s1600/picture%2B1.jpg)
Mission Mountain Wilderness
![](https://www.mdpi.com/pharmaceutics/pharmaceutics-15-01796/article_deploy/html/images/pharmaceutics-15-01796-g003.png)
Pharmaceutics, Free Full-Text
![](https://www.biochempeg.com/usr/uploads/3/202111/Trodelvy.png)
ADC Drug Trodelvy Shows Positive Efficacy In three Types of Cancers
![](https://www.mdpi.com/biomolecules/biomolecules-13-01207/article_deploy/html/images/biomolecules-13-01207-g001.png)
Biomolecules, Free Full-Text
![](https://www.researchgate.net/publication/371953176/figure/fig2/AS:11431281189858659@1695176972594/Immunosurveillance-targets-in-early-stage-clinical-trials-for-TNBC-Overview-of-the_Q320.jpg)
PDF) Exploiting Therapeutic Vulnerabilities in Triple-Negative
![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ebb8f882a3ff9e5bebaa311126dcebcf4176a21-4650x6450.png?fit=crop&auto=format)
Recap: The Use of Sacituzumab Govitecan in Triple-Negative Breast Cancer
![](https://www.mdpi.com/jpm/jpm-11-00652/article_deploy/html/images/jpm-11-00652-g001.png)
Sacituzumab Earns Regular FDA Approval For TNBC NCI